Publication

Article

Heal

Spring 2019
Volume7
Issue 2

Findings Confirm Exercise Benefit for Kidney Cancer Survivors

Author(s):

Kidney cancer survivors who follow recommendations for physical activity experience improved quality of life, but few individuals adhere to the guidelines, according to recent findings.

Kidney cancer survivors who follow recommendations for physical activity experience improved quality of life, but few individuals adhere to the guidelines, according to recent findings.

Cancer survivors should engage in 150 minutes of moderate or 75 minutes of vigorous aerobic activity weekly, or an equivalent combination, according to the American Cancer Society and the American College of Sports Medicine. Both groups also recommend at least two days a week of strength training that hits all muscle groups.

The study, published in Psycho-Oncology, surveyed 703 kidney cancer survivors using a provincial registry in Canada to determine how often the combined guidelines were met and if they were associated with quality of life.

Most survivors were men, had localized kidney cancer and were more than five years out from their initial diagnosis. The average age was 65; average body mass index, 28.5.

Researchers learned that 65.1 percent of the participants met neither guideline, 15.9 percent met only the aerobic guideline, 10.1 percent met both guidelines and 8.8 percent met only the strength training guideline.

Those who met both guidelines experienced better quality of life compared with those who met just one, and meeting at least one guideline was better than none.

“Our study suggests that exercise programs should target both aerobic and strength exercise for additional (quality of life) benefits in (kidney cancer survivors),” the researchers wrote.

Related Videos
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Related Content